Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.08 AUD
Change Today -0.003 / -3.85%
Volume 227.0K
AVH On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 9:51 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

avita medical ltd (AVH) Snapshot

Open
A$0.08
Previous Close
A$0.08
Day High
A$0.08
Day Low
A$0.08
52 Week High
09/16/14 - A$0.12
52 Week Low
04/7/15 - A$0.06
Market Cap
31.9M
Average Volume 10 Days
142.6K
EPS TTM
A$-0.02
Shares Outstanding
425.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AVITA MEDICAL LTD (AVH)

Related News

No related news articles were found.

avita medical ltd (AVH) Related Businessweek News

No Related Businessweek News Found

avita medical ltd (AVH) Details

Avita Medical Limited, a medical device company, develops and distributes regenerative medicine and respiratory products in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The company develops and distributes tissue-engineered products for the treatment of wounds and other skin defects. Its lead product is ReCell, an autologous cell harvesting, processing, and delivery technology that enable surgeons and clinicians to treat skin defects using the patient's own cells in a regenerative process for use in various wound, plastic, reconstructive, burn, and cosmetic procedures. The company also manufactures and sells a range of spacers, including Funhaler incentive asthma spacer for the paediatric market; and Breath-A-Tech spacer for the adolescent and adult markets. The company has collaboration with the University of Huddersfield. Avita Medical Limited is headquartered in Royston, the United Kingdom.

avita medical ltd (AVH) Top Compensated Officers

Chief Financial Officer and Chief Operating O...
Total Annual Compensation: A$328.9K
Vice President of Research & Technology
Total Annual Compensation: A$235.0K
Company Secretary
Total Annual Compensation: A$36.0K
General Manager of Asia Pacific
Total Annual Compensation: A$184.9K
Vice President of Operations and Quality
Total Annual Compensation: A$153.4K
Compensation as of Fiscal Year 2014.

avita medical ltd (AVH) Key Developments

Avita Medical Limited Announces New Research Partnership with University of Huddersfield

Avita Medical Ltd. announced that it has forged a partnership with England's University of Huddersfield to explore the mechanism of Regenerative Epithelial Suspension (RES(TM)) - from Avita's ReCell(r) device - to better understand its ability to effectively treat burns, hard-to-heal wounds and skin trauma. The objective of the research is to provide greater understanding of the cellular interactions present in RES(TM) and the roles these play in regenerating natural, healthy skin. It is anticipated that the results of this research will help enable clinicians to make more informed patient selection leading to superior clinical outcomes. In the coming months, Dr. Nikolaos Georgopoulos, Senior lecturer in Biological Sciences, Dr. Karen Ousey, Reader in Advancing Clinical Practice, and Professor Barbara Conway, Professor of Pharmaceutics -- all from the Institute of Skin Integrity and Infection Prevention at the University of Huddersfield -- will assess the ReCell(r) device using donated human skin to produce RES(TM). The investigators will examine the behaviour of the skin cells in RES(TM) using sophisticated analysis techniques to reveal ongoing cellular interactions. The resulting new information regarding the mechanism within RES(TM) will be used to advance clinical practice, education, and product development.

Avita Medical Limited Reports Sales Results for the Fourth Quarter Ended June 30, 2015

Avita Medical Limited reported sales results for the fourth quarter ended June 30, 2015. Fourth quarter total sales (for regenerative as well as legacy respiratory products) increased by 25% year-over-year and 51% versus the previous quarter.

Avita Medical Limited, Annual General Meeting, Aug 24, 2015

Avita Medical Limited, Annual General Meeting, Aug 24, 2015., at 11:00 E. Australia Standard Time. Location: Level 12, 15 William Street. Agenda: To consider and approve ratification of prior issue of shares; to consider and approve ratification of prior issue of shares; to consider and approve to issue shares under placement; to consider and adopt of employee share plan incentive plan; and to consider and approve other business.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVH:AU A$0.08 AUD -0.003

AVH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVH.
View Industry Companies
 

Industry Analysis

AVH

Industry Average

Valuation AVH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVITA MEDICAL LTD, please visit www.avitamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.